When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Florbetapir (18F) - Wikipedia

   en.wikipedia.org/wiki/Florbetapir_(18F)

   Florbetapir (18 F), sold under the brand name Amyvid, is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18 that was approved for use in the United States in 2012, [4] as a diagnostic tool for Alzheimer's disease.

3. US removes coverage curb on PET scans for Alzheimer's ... - AOL

   www.aol.com/news/u-agency-removes-coverage-curb...

   “Amyloid PET scans are a proven tool and can be an important part of Alzheimer’s diagnosis and treatment,” Maria Carrillo, chief science officer of the Alzheimer’s Association, said in a ...

4. Avid Radiopharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Avid_Radiopharmaceuticals

   In results presented in July 2010 to an international conference on Alzheimer's disease held in Hawaii, the company showed that for 34 out of the 35 hospice patients who had been scanned, the initial scan results were confirmed when pathologists counted plaque under a microscope and when a computerized scan of the plaque was performed on ...

5. Flutemetamol (18F) - Wikipedia

   en.wikipedia.org/wiki/Flutemetamol_(18F)

   The initial flutemetamol PET scan resulted in 43 positive and 25 negative results for cerebral cortisol amyloid status. 69 of the initial patients died within 13 months of the flutemetamol PET scan. The autopsy for 67 of those patients determined the global brain neuritic plaque density category.

6. CMS proposes broader coverage of PET scans for Alzheimer's ...

   www.aol.com/news/cms-proposes-broader-coverage...

   "Today's announcement about Medicare coverage of amyloid PET scans fulfills CMS' commitment to allow broader coverage of this diagnostic test," said CMS Administrator Chiquita Brooks-LaSure.

7. NINCDS-ADRDA Alzheimer's Criteria - Wikipedia

   en.wikipedia.org/wiki/NINCDS-ADRDA_Alzheimer's...

   Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...